FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
12 letters match. Newest first.
-
DevicesCCIC Huatongwei International Inspection Co., Ltd.
FDA warns CCIC Huatongwei after inspection found copied data and missing records in medical device safety tests.
High risk -
DrugsMark J. Savant, M.D
FDA warns clinical investigator Mark J. Savant, M.D., over protocol dosing and eligibility failures and missing informed consent in a drug trial.
High risk -
DrugsMehran Michael Bahrami, M.D.
FDA warns clinical investigator Dr. Mehran Michael Bahrami over protocol violations and missing records in investigational drug trials.
High risk -
DrugsLouisiana State University Health Science Center IRB
FDA warns Louisiana State University Health Science Center IRB about missed continuing reviews and unreported study terminations for drug research.
Medium -
DevicesMid-Link Testing Company, Ltd
FDA warns Mid-Link Testing over unreliable Good Laboratory Practice (GLP) safety data for medical device tests.
High risk -
DevicesSanitation & Environmental Technology Institute dba SDWH
FDA found GLP violations in SDWH's nonclinical testing of medical devices, raising doubts about safety data.
High risk -
DrugsJeffrey W. Taub, M.D./Children's Hospital of Michigan
FDA warns Detroit investigator over pediatric drug trial protocol deviations and lapsed IRB approval.
High risk -
DrugsAntonio E. Blanco, M.D./Vista Health Research, LLC
FDA cited Dr. Antonio E. Blanco/Vista Health Research for enrolling ineligible trial subjects and missing required safety imaging.
High risk -
DrugsAngela M. Stupi, M.D.
Clinical investigator Angela M. Stupi, M.D. enrolled ineligible subjects and injected study drug at wrong body sites in two trials.
High risk -
DrugsRobert J. Hayashi, M.D./Washington University School of Medicine, Department of Pediatrics
FDA warned Dr. Robert J. Hayashi over protocol deviations in pediatric drug trials that exposed a child to unnecessary study drug and invasive procedures.
High risk -
BiologicsToxikon Corporation/Labcorp Bedford LLC
FDA warned Toxikon/Labcorp Bedford over GLP violations in a biologics nonclinical study, including incorrect kidney-function calculations and failed QA review.
Medium -
DrugsIgnacio J. Rodriguez, MD
FDA warns Dr. Ignacio J. Rodriguez for enrolling ineligible subjects and giving study drug without required checks in a clinical trial.
High risk